Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi

Ashi Sae Yang/iStock via Getty Images Inhibrx Biosciences, Inc. (NASDAQ:INBX) is a biotech that should be on everyone's radar. The reason why I state that is because it was able to make significant progress relating to the development of a drug known as INBRX-101 for the treatment of patients with alpha-1 antitrypsin deficiency. With such remarkable progress made, plus the ability to advance this clinical candidate into a phase 3 study, it garnered interest from Sanofi (SNY). That is, this big pharmaceutica ...